Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
AMEX
Unprofitable
EPS improving
Unprofitable
EPS improving
72M
Biotechnology
Next Earning date - 20 Mar 2025
72M
Biotechnology
Next Earning date - 20 Mar 2025
Relative Strenght
5Volume Buzz
-83%Earning Acce
YesDist 52w H.
52%